Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSkinbiotherap. Regulatory News (SBTX)

Share Price Information for Skinbiotherap. (SBTX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.25
Bid: 9.00
Ask: 9.50
Change: -0.11 (-1.19%)
Spread: 0.50 (5.556%)
Open: 9.25
High: 9.14
Low: 9.14
Prev. Close: 9.25
SBTX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

REX Retail Offer

15 Dec 2022 16:32

RNS Number : 8962J
SkinBioTherapeutics PLC
15 December 2022
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, OR INTO OR WITHIN THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, SOUTH AFRICA OR JAPAN, OR ANY MEMBER STATE OF THE EEA, OR ANY OTHER JURISDICTION WHERE, OR TO ANY OTHER PERSON TO WHOM, TO DO SO MIGHT CONSTITUTE A VIOLATION OR BREACH OF ANY APPLICABLE LAW OR REGULATION. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.

 

THE COMMUNICATION OF THIS ANNOUNCEMENT AND ANY OTHER DOCUMENTS OR MATERIALS RELATING TO THE REX RETAIL OFFER AS A FINANCIAL PROMOTION IS ONLY BEING MADE TO, AND MAY ONLY BE ACTED UPON BY, THOSE PERSONS IN THE UNITED KINGDOM FALLING WITHIN ARTICLE 43 OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005, AS AMENDED (WHICH INCLUDES AN EXISTING MEMBER OF SKINBIOTHERAPEUTICS PLC). ANY INVESTMENT OR INVESTMENT ACTIVITY TO WHICH THIS ANNOUNCEMENT RELATES IS AVAILABLE ONLY TO SUCH PERSONS AND WILL BE ENGAGED IN ONLY WITH SUCH PERSONS. THIS ANNOUNCEMENT IS FOR INFORMATIONAL PURPOSES ONLY, AND DOES NOT CONSTITUTE OR FORM PART OF ANY OFFER OR INVITATION TO SELL OR ISSUE, OR ANY SOLICITATION OF AN OFFER TO PURCHASE OR SUBSCRIBE FOR, ANY SECURITIES OF SKINBIOTHERAPEUTICS PLC.

 

 

15 December 2022

 

SkinBioTherapeutics plc

 

REX Retail Offer

 

SkinBioTherapeutics plc ("SkinBioTherapeutics" or the "Company") is pleased to announce a retail offer via REX (the "REX Retail Offer") of ordinary shares ("Ordinary Shares") of 1 pence each in the capital of the Company (the "REX Retail Offer Shares")

 

In addition to the REX Retail Offer, the Company is also conducting a placing of new ordinary shares (the "Placing Shares" and together with the REX Retail Offer Shares, the "New Ordinary Shares") through a bookbuild process (the "Placing"). The price of the Placing Shares is £0.16 (the "Placing Price"), which represents a 7.2 per cent. discount to the closing price on 14 December 2022 (being the last business day prior to the announcement of the Placing and the REX Retail Offer). The price of the REX Retail Offer Shares is equal to the Placing Price.

 

A separate announcement has been made regarding the Placing and its terms. For the avoidance of doubt, the REX Retail Offer is not part of the Placing.

 

The REX Retail Offer and the Placing are conditional on the New Ordinary Shares being admitted to trading on the AIM market of the London Stock Exchange plc ("Admission"). Admission is expected to take place at 8.00 a.m. on 5 January 2023. Completion of the REX Retail Offer is conditional, inter alia, upon the completion of the Placing.

 

REX Retail Offer

 

The Company values its retail shareholder base and believes that it is appropriate to provide its existing retail shareholders in the United Kingdom the opportunity to participate in the REX Retail Offer. Therefore the Company is making the REX Retail Offer open to eligible investors in the United Kingdom following release of this announcement through certain financial intermediaries. 

 

Existing shareholders can contact their broker or wealth manager to participate in the REX Retail Offer.

 

The REX Retail Offer is expected to close at 4.30 p.m. on 20 December 2022. Eligible shareholders should note that financial intermediaries may have earlier closing times.

 

Retail brokers or wealth managers wishing to participate in the REX Retail Offer on behalf of their clients, should contact info@rexretail.com.

 

To be eligible to participate in the REX Retail Offer, applicants must be a customer of a participating intermediary and, as at the date hereof or will be, prior to placing an order for REX Retail Offer Shares, shareholders in the Company, which may include individuals aged 18 years or over, companies and other bodies corporate, partnerships, trusts, associations and other unincorporated organisations.

The terms and conditions on which investors subscribe will be provided by the relevant financial intermediaries including relevant commission or fee charges.

 

The Company reserves the right to scale back any order under the REX Retail Offer at its discretion. The Company reserves the right to reject any application for subscription under the REX Retail Offer without giving any reason for such rejection.

 

It is vital to note that once an application for REX Retail Offer Shares has been made and accepted via an intermediary, it cannot be withdrawn.

 

The New Ordinary Shares will, when issued, be credited as fully paid and will rank pari passu in all respects with existing Ordinary Shares including the right to receive all dividends and other distributions declared, made or paid after their date of issue.

 

It is a term of the REX Retail Offer that the total value of the REX Retail Offer Shares available for subscription at the Placing Price does not exceed £1.0 million. 

 

The REX Retail Offer is offered in the United Kingdom under the exemption from the requirement to publish a prospectus in section 86(1)(e) of FSMA. As such, there is no need for publication of a prospectus pursuant to the Prospectus Regulation Rules of the Financial Conduct Authority, or for approval of the same by the Financial Conduct Authority. The REX Retail Offer is not being made into any jurisdiction other than the United Kingdom.

 

No offering document, prospectus or admission document has been or will be prepared or submitted to be approved by the Financial Conduct Authority (or any other authority) in relation to the REX Retail Offer, and investors' commitments will be made solely on the basis of the information contained in this announcement and information that has been published by or on behalf of the Company prior to the date of this announcement by notification to a Regulatory Information Service in accordance with the Financial Conduct Authority's Disclosure Guidance and Transparency Rules, the Market Abuse Regulation (EU Regulation No. 596/2014) ("MAR") and MAR as it forms part of United Kingdom law by virtue of the European Union (Withdrawal) Act 2018 (as amended).

Investors should make their own investigations into the merits of an investment in the Company. Nothing in this announcement amounts to a recommendation to invest in the Company or amounts to investment, taxation or legal advice.

 

It should be noted that a subscription for REX Retail Offer Shares and investment in the Company carries a number of risks. Investors should take independent advice from a person experienced in advising on investment in securities such as the REX Retail Offer Shares if they are in any doubt.

 

An investment in the Company will place capital at risk. The value of your investment in the Company and any income from it is not guaranteed and can fall as well as rise due to stock market and currency movements. When you sell your investment, you may get back less than the amount originally invested.

 

Neither past performance nor any forecasts should be considered a reliable indicator of future results.

 

For Further Information

 

SkinBioTherapeutics plc

Stuart J. Ashman, CEO

Manprit Randhawa, CFO

Tel: +44 (0) 191 495 7325

Cenkos Securities Plc (Nominated Adviser & Broker)

Giles Balleny, Max Gould (Corporate Finance)

Dale Bellis, Tamar Cranford-Smith (Sales)

Tel: +44 (0) 20 7397 8900

Instinctif Partners (financial press)

Melanie Toyne-Sewell / Tim Field 

Tel: +44 (0) 20 7457 2020

SkinBio@instinctif.com

REX Retail

 

Info@rexretail.com

 

 

 

 

Further information on the Company can be found on its website at https://www.skinbiotherapeutics.com/

 

The Company's LEI is 213800YMQOCB23FX6I06.

 

This announcement should be read in its entirety. In particular, the information in the "Important Notices" section of the announcement should be read and understood.

 

Important Notices

 

The content of this announcement, which has been prepared by and is the sole responsibility of the Company.

 

This announcement and the information contained herein is not for release, publication or distribution, directly or indirectly, in whole or in part, in or into or from the United States (including its territories and possessions, any state of the United States and the District of Columbia (the "United States" or "US")), Australia, Canada, New Zealand, Japan, the Republic of South Africa, any member state of the EEA or any other jurisdiction where to do so might constitute a violation of the relevant laws or regulations of such jurisdiction.

 

The REX Retail Offer Shares have not been and will not be registered under the US Securities Act of 1933, as amended (the "US Securities Act") or under the applicable state securities laws of the United States and may not be offered or sold directly or indirectly in or into the United States. No public oering of the REX Retail Offer Shares is being made in the United States. The REX Retail Offer Shares are being oered and sold outside the United States in "oshore transactions", as dened in, and in compliance with, Regulation S under the US Securities Act ("Regulation S") to non-US persons (within the meaning of Regulation S). In addition, the Company has not been, and will not be, registered under the US Investment Company Act of 1940, as amended.

 

This announcement does not constitute an offer to sell or issue or a solicitation of an offer to buy or subscribe for REX Retail Offer Shares in the United States, Australia, Canada, New Zealand, Japan, the Republic of South Africa, any member state of the EEA or any other jurisdiction in which such offer or solicitation is or may be unlawful. No public offer of the securities referred to herein is being made in any such jurisdiction.

 

This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America. This announcement is not an offer of securities for sale into the United States. The securities referred to herein have not been and will not be registered under the US Securities Act, and may not be offered or sold in the United States, except pursuant to an applicable exemption from registration. No public offering of securities is being made in the United States.

 

The distribution of this announcement may be restricted by law in certain jurisdictions and persons into whose possession any document or other information referred to herein comes should inform themselves about and observe any such restriction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

 

REX is a proprietary technology platform owned and operated by Peel Hunt LLP (registered address at 7th Floor, 100 Liverpool Street, London EC2M 2AT; FRN 530083). Peel Hunt LLP ("Peel Hunt") is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting exclusively for the Company and for no-one else and will not regard any other person (whether or not a recipient of this announcement) as its client in relation to the REX Retail Offer and will not be responsible to anyone other than the Company for providing the protections afforded to its clients, nor for providing advice in connection with the REX Retail Offer, Admission and the other arrangements referred to in this announcement.

 

The value of Ordinary Shares and the income from them is not guaranteed and can fall as well as rise due to stock market and currency movements. When you sell your investment, you may get back less than you originally invested. Figures refer to past performance and past performance is not a reliable indicator of future results. Returns may increase or decrease as a result of currency fluctuations.

 

Certain statements in this announcement are forward-looking statements which are based on the Company's expectations, intentions and projections regarding its future performance, anticipated events or trends and other matters that are not historical facts. These forward-looking statements, which may use words such as "aim", "anticipate", "believe", "intend", "estimate", "expect" and words of similar meaning, include all matters that are not historical facts. These forward-looking statements involve risks, assumptions and uncertainties that could cause the actual results of operations, financial condition, liquidity and dividend policy and the development of the industries in which the Company's businesses operate to differ materially from the impression created by the forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Given those risks and uncertainties, prospective investors are cautioned not to place undue reliance on forward-looking statements.

 

These forward-looking statements speak only as at the date of this announcement and cannot be relied upon as a guide to future performance. The Company and Peel Hunt expressly disclaim any obligation or undertaking to update or revise any forward-looking statements contained herein to reflect actual results or any change in the assumptions, conditions or circumstances on which any such statements are based unless required to do so by the Financial Conduct Authority, the London Stock Exchange or applicable law.

 

The information in this announcement is for background purposes only and does not purport to be full or complete. None of Peel Hunt or any of its affiliates, accepts any responsibility or liability whatsoever for, or makes any representation or warranty, express or implied, as to this announcement, including the truth, accuracy or completeness of the information in this announcement (or whether any information has been omitted from the announcement) or any other information relating to the Company or associated companies, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising from any use of the announcement or its contents or otherwise arising in connection therewith. Peel Hunt and its affiliates, accordingly disclaim all and any liability whether arising in tort, contract or otherwise which they might otherwise be found to have in respect of this announcement or its contents or otherwise arising in connection therewith.

 

Any indication in this announcement of the price at which the Ordinary Share have been bought or sold in the past cannot be relied upon as a guide to future performance. Persons needing advice should consult an independent financial adviser. No statement in this announcement is intended to be a profit forecast and no statement in this announcement should be interpreted to mean that earnings or target dividend per share of the Company for the current or future financial years would necessarily match or exceed the historical published earnings or dividends per share of the Company.

 

Neither the content of the Company's website (or any other website) nor the content of any website accessible from hyperlinks on the Company's website (or any other website) is incorporated into or forms part of this announcement. The REX Retail Offer Shares to be issued or sold pursuant to the REX Retail Offer will not be admitted to trading on any stock exchange other than the London Stock Exchange.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOEQELFFLLLFFBF
Date   Source Headline
11th Apr 202411:44 amRNSHolding(s) in Company
5th Apr 20247:00 amRNSConversion Notice & Total Voting Rights
22nd Mar 20247:00 amRNSHalf-year Report
18th Mar 202411:36 amRNSHolding(s) in Company
18th Mar 20247:00 amRNSNew research project and CSO to return to academia
12th Mar 20247:00 amRNSConversion Notice and Total Voting Rights
8th Mar 20249:43 amRNSNotice of Results
28th Feb 202412:41 pmRNSConversion notice and alternative financing
27th Feb 20247:00 amRNSPositive Interim AxisBiotix Acne study results
20th Feb 20247:00 amRNSDermatonics to launch Once Heel Balm in AMEA
9th Feb 20247:00 amRNSConversion Notice and Total Voting Rights
6th Feb 20247:31 amRNSDermatonics Full Year trading update
26th Jan 20247:00 amRNSCompletion of Acquisition of Dermatonics
25th Jan 20247:00 amRNSAcquisition of Dermatonics
25th Jan 20247:00 amRNS£5.0m Convertible Bond Facility & First Drawdown
29th Dec 202310:49 amRNSResult of AGM
29th Dec 20238:13 amRNSUpdate on transaction timelines to early 2024
6th Dec 20237:00 amRNSNotice of AGM and posting of Annual Report
30th Nov 20235:25 pmRNSFinal Results
30th Nov 20237:00 amRNSAxisBiotix-Psâ„¢ to launch on Amazon UK
24th Nov 20237:00 amRNSHolding(s) in Company
23rd Nov 20233:37 pmRNSHolding(s) in Company
22nd Nov 20237:00 amRNSUpdate regarding Nominated Adviser and Broker
21st Nov 20237:00 amRNSResult of Retail Offer
17th Nov 20237:00 amRNSResult of Placing
16th Nov 20234:35 pmRNSRetail Offer
16th Nov 20234:33 pmRNSPlacing and Retail Offer
25th Oct 20237:25 amRNSAcne study, Trading and Auditor updates
19th Oct 20237:00 amRNSExtension of Croda contract for SkinBiotixâ„¢
15th Sep 20239:00 amRNShealth authority approval for AxisBiotix in France
5th Sep 20237:00 amRNSUpdate on acne programme
31st Jul 202312:51 pmRNSHolding(s) in Company
21st Jun 20237:00 amRNSRegulatory Approval
14th Jun 20234:46 pmRNSBusiness progress update
10th May 20237:00 amRNSSkinBiotix and AxisBiotix Update
14th Apr 20237:00 amRNSDirector/PDMR Shareholding
28th Mar 20231:45 pmRNSReplacement Half-year Report
28th Mar 20237:00 amRNSHalf-year Report
27th Mar 20234:35 pmRNSPrice Monitoring Extension
9th Mar 20235:18 pmRNSDirector/PDMR Shareholding
9th Mar 20235:18 pmRNSDirector/PDMR Shareholding
7th Mar 20237:00 amRNSAxisBiotix-Ps™ approved for launch in Europe
20th Feb 202311:17 amRNSHolding(s) in Company
31st Jan 202311:15 amRNSResult of General Meeting
30th Jan 20234:28 pmRNSHolding(s) in Company
30th Jan 20239:00 amRNSHolding(s) in Company
16th Jan 20234:40 pmRNSSecond Price Monitoring Extn
16th Jan 20234:35 pmRNSPrice Monitoring Extension
6th Jan 20237:44 amRNSNotice of General Meeting - Replacement
6th Jan 20237:00 amRNSNotice of General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.